Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an update.
Recordati has provided an update on its ongoing share buyback program, launched in December 2025 under a shareholder resolution to support existing and future stock option and performance share plans for group management. Between 26 and 30 January 2026, the company repurchased 68,614 ordinary shares on the Italian Stock Exchange at a weighted average price of €46.5320, bringing its treasury shareholding to 5,062,352 shares, equivalent to 2.421% of its share capital, reflecting an active capital management strategy aligned with long-term incentive schemes for key personnel.
The most recent analyst rating on (IT:REC) stock is a Sell with a EUR48.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group listed on Borsa Italiana that develops, produces, commercializes and licenses active pharmaceutical ingredients and finished products for both general and specialist medicine, as well as treatments for rare diseases. Founded in the 1920s in Northern Italy, it now operates in around 150 countries across EMEA, the Americas and APAC with more than 4,580 employees, pursuing a mission focused on broad access to healthcare and addressing both common and rare conditions.
Average Trading Volume: 303,962
Technical Sentiment Signal: Hold
Current Market Cap: €9.56B
Find detailed analytics on REC stock on TipRanks’ Stock Analysis page.